CYP Induction-Mediated Drug Interactions: in Vitro Assessment and Clinical Implications
The DOI matches its Crossref record; 256 of the 257 references it cites were found in a registry or an index.
Abstract
Cytochrome P450 (CYP) induction-mediated interaction is one of the major concerns in clinical practice and for the pharmaceutical industry. There are two major issues associated with CYP induction: a reduction in therapeutic efficacy of comedications and an induction in reactive metabolite-induced toxicity. Because CYP induction is a metabolic liability in drug therapy, it is highly desirable to develop new drug candidates that are not potent CYP inducer to avoid the potential of CYP induction-mediated drug interactions. For this reason, today, many drug companies routinely include the assessment of CYP induction at the stage of drug discovery as part of the selection processes of new drug candidates for further clinical development. The purpose of this article is to review the molecular mechanisms of CYP induction and the clinical implications, including pharmacokinetic and pharmacodynamic consequences. In addition, factors that affect the degree of CYP induction and extrapolation of in vitro CYP induction data to in vivo situations will also be discussed. Finally, assessment of the potential of CYP induction at the drug discovery and development stage will be discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
The Pharmacological Basis of Therapeutics
(1976) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/33.4.373a · Cited by 8,209
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785
Cytochrome P-450: Structure, Mechanism, and Biochemistry
de Montellano, O., & Paul, R. (1986) · Medical Entomology and Zoology · Cited by 2,663
Poland, A., & Knutson, J. C. (1982) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.22.040182.002505 · Cited by 2,515
A physiological approach to hepatic drug clearance
Wilkinson, G. R., & Shand, D. G. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1975184377 · Cited by 1,873
Lehmann, J. M., McKee, D. D., Watson, M. A., Willson, T. M., Moore, J. T., & Kliewer, S. A. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3703 · Cited by 1,576
An Orphan Nuclear Receptor Activated by Pregnanes Defines a Novel Steroid Signaling Pathway
Kliewer, S. A., Moore, J. T., Wade, L., Staudinger, J. L., Watson, M. A., Jones, S. A., McKee, D. D., Oliver, B. B., Willson, T. M., Zetterström, R. H., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)80900-9 · Cited by 1,539
Poland, A., Glover, E., & Kende, A. S. (1976) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)33205-2 · Cited by 1,370
Jaeschke, H. (2002) · Toxicological Sciences · doi:10.1093/toxsci/65.2.166 · Cited by 1,304
Gelboin, H. V. (1980) · Physiological Reviews · doi:10.1152/physrev.1980.60.4.1107 · Cited by 1,280
Research works printed but not linked: 27
- H. V. Gelboin, 1980, Pharmacol. Rev., 60, 1107
- J. M. Silva, 1998, Drug Metab. Dispos., 26, 490
- W. El-Sankary, 2001, Drug Metab. Dispos., 29, 1499
- R. C. Pollenz, 1994, Mol. Pharmacol., 45, 428
- J.-M. Passcussi, 2000, Mol. Pharmacol., 58, 1441, 10.1124/mol.58.6.1441 · doi:10.1124/mol.58.6.1441 · Paper page
- T. A. Kocarek, 1995, Drug Metab. Dispos., 23, 415
- S. M. Fontaine, 2001, Drug Metab. Dispos., 29, 1236
- J. L. Barwick, 1996, Mol. Pharmacol., 50, 10
- T. Shimada, 1994, J. Pharmacol. Exp. Ther., 270, 414
- K. E. Thummel, 1994, J. Pharmacol. Exp. Ther., 271, 557
- M. F. Paine, 1997, J. Pharmacol. Exp. Ther., 283, 1552
- E. T. Morgan, 2001, Drug Metab. Dispos., 29, 207
- T. K. Chang, 1997, Cancer Res., 57, 1946
- A. Poland, 1990, Mol. Pharmacol., 38, 306
- G. R. Wilkinson, 1987, Pharmacol. Rev., 39, 1
- N. Holtbecker, 1996, Drug Metab. Dispos., 24, 1121
- S. Gerbal-Chaloin, 2001, Drug Metab. Dispos., 29, 242
- L. Drocourt, 2001, Drug Metab. Dispos., 29, 1325
- S. C. Nallami, 2003, Epilepsia, 44, 1428
- I. Waziers de, 1990, J. Pharmacol. Exp. Ther., 253, 387
- R. A. O'Reilly, 1987, Adv. Exp. Med. Biol., 214, 205
- Y. Caraco, 1997, J. Pharmacol. Exp. Ther., 281, 330
- W. D. Fiske, D. Mayers, and K. Wagner. Pharmacokinetics of DMP 266 and indinavir multiple oral doses in HIV-1 infected individuals [abstract no. 568]. 4th Conference on Retroviruses and Opportunistic Infections. 1996, Jan 28–Feb 1. Washington, DC.
- A. H. Conney, 2003, Cancer Res., 63, 7005
- A. Cantani, 2005, Eur. Rev. Med. Pharmacol. Sci., 9, 23
- M. Morimoto, 1995, Hepatology, 21, 1610
- E. L. LeCluyse, 1996, Model Systems for Biopharmaceutical Assessment of Drug Absorption and Metabolism, 125
Cited by
A liver-on-a-chip platform with bioprinted hepatic spheroids
Bhise, N. S., Manoharan, V., Massa, S., Tamayol, A., Ghaderi, M., Miscuglio, M., Lang, Q., Shrike Zhang, Y., Shin, S. R., Calzone, G., et al. (2016) · Biofabrication · doi:10.1088/1758-5090/8/1/014101 · Cited by 615
Obach, R. S., Walsky, R. L., & Venkatakrishnan, K. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.012633 · Cited by 460
The mechanisms of pharmacokinetic food-drug interactions – A perspective from the UNGAP group
Koziolek, M., Alcaro, S., Augustijns, P., Basit, A. W., Grimm, M., Hens, B., Hoad, C. L., Jedamzik, P., Madla, C. M., Maliepaard, M., et al. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.04.003 · Cited by 385
Organotypic liver culture models: meeting current challenges in toxicity testing
LeCluyse, E. L., Witek, R. P., Andersen, M. E., & Powers, M. J. (2012) · Critical Reviews in Toxicology · doi:10.3109/10408444.2012.682115 · Cited by 363
Predicting Drug-Target Interaction Networks Based on Functional Groups and Biological Features
He, Z., Zhang, J., Shi, X.-H., Hu, L.-L., Kong, X., Cai, Y.-D., & Chou, K.-C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009603 · Cited by 288
Metadata
- Authors
- Lin, J. H.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Lin, Jiunn H.
- ORCID
- Lin, Jiunn H.
- Venue
- Pharmaceutical Research
- Published
- 2006-05-26
- Volume
- 23
- Issue
- 6
- Pages
- 1089-1116
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W1997271604
- Cited by
- 264
- References
- 257
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 7 · 2023: 3 · 2022: 10 · 2021: 11 · 2020: 13 · 2019: 7 · 2018: 8 · 2017: 9 · 2016: 11 · 2015: 13 · 2014: 11 · 2013: 15 · 2012: 22
- FWCI
- 3.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Pharmaceutical Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- cytochrome P450 induction, drug interactions, CYP inducers, in vitro-in vivo extrapolation, pharmacokinetics, pharmacodynamics, drug discovery, drug development, treatment efficacy
- MeSH terms
- Pregnane X Receptor, Constitutive Androstane Receptor, Animals, Drug Interactions, Enzyme Induction, Humans, Liver, Pharmacokinetics, Pharmacology, Receptors, Steroid, Species Specificity, Transcription Factors, Genetic Variation, Drug Design, Receptors, Cytoplasmic and Nuclear, Receptors, Aryl Hydrocarbon, Cytochrome P-450 CYP2B1, Cytochrome P-450 CYP2E1, Receptor Cross-Talk, Cytochrome P-450 CYP3A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CYP Induction-Mediated Drug Interactions: in Vitro Assessment and Clinical Implications. https://app.cochat.ai/papers/10.1007/s11095-006-0277-7
- The paper
- Lin, J. H. (2006). CYP Induction-Mediated Drug Interactions: in Vitro Assessment and Clinical Implications. Pharmaceutical Research. https://doi.org/10.1007/s11095-006-0277-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.